Previous 10 | Next 10 |
home / stock / xvipf / xvipf news
GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) In 2014, XVIVO introduced an innovative liver technology to the Italian market, designed for oxygenated perfusion prior to transplantation. Today, we are proud to announce that we have reached...
GOTHENBURG, SWEDEN / ACCESSWIRE / December 14, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) As communicated on July 12, 2023, XVIVO has decided to close its´ PrimECC study for further patient inclusions and to evaluate potential strategic opportunities. The decision has been mad...
GOTHENBURG, SE / ACCESSWIRE / November 3, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The results of the clinical trial conducted in Australia and New Zealand on XVIVO's heart technology were earlier this week published in the prestigious scientific journal, The Journal of Heart and...
GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Third quarter 2023 (July 1 - September 30) • Net sales amounted to SEK 146.6 million (96.8), corresponding to an increase of 51 percent in SEK and 42 percent in local currencies. ...
GOTHENBURG, SWEDEN / ACCESSWIRE / October 23, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) On October 14, 2023 Duke University Hospital in Durham, N.C., performed the first heart transplant in the U.S. using XVIVO's Non-Ischemic Heart Preservation (NIHP) device and solution as part o...
GOTHENBURG, SWEDEN / ACCESSWIRE / October 6, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023. The presentation will be held in English. Time: Tuesday, October 24 at 2.00 pm...
GOTHENBURG, SWEDEN / ACCESSWIRE / September 29, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The following members have been appointed to XVIVO Perfusion's nomination committee for the 2024 annual general meeting: Henrik Blomquist, appointed by Bure Equity AB Fredrik Stenkil, appoi...
GOTHENBURG, SWEDEN / ACCESSWIRE / July 25, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The US Food & Drug Administration (FDA) has approved XVIVO's Investigational Device Exemption (IDE) supplement for its heart preservation clinical trial to now include Donation after Circulato...
GOTHENBURG, SWEDEN / ACCESSWIRE / July 13, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) "Continued momentum for our business" Second quarter 2023 (Apr 1 - Jun 30) • Net sales amounted to SEK 154.6 million (94.3), corresponding to an increase of 64 percent in SEK and 52 perc...
GOTHENBURG, SE / ACCESSWIRE / July 12, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) PrimECC is a solution used to prime the heart-lung machine before heart-surgery. It is a CE-marked and patent-protected product and is developed to reduce postoperative complications. In 2020 a study ...
News, Short Squeeze, Breakout and More Instantly...
Xvivo Perfusion Ab Ord Company Name:
XVIPF Stock Symbol:
OTCMKTS Market:
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) First quarter 2024 (Jan 1 - Mar 31) • Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted ...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO's clinical trial, NIHP2019, in heart transplantation were pres...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to this press release in pdf format and in ESEF format (European Single Electronic Format) and is...